Efficacy and Safety of Ledipasvir/Sofosbuvir With and Without Ribavirin in Patients With Chronic HCV Genotype 1 Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ION Trials

Conclusions. OST and drug use during HCV therapy did not impact treatment completion, adherence, SVR12, or safety.
Clinical Trials Registration. ION-1 (NCT01701401); ION-2 (NCT01768286); and ION-3 (NCT01851330).

Source: Clinical Infectious Diseases - November 11, 2016 Category: Infectious Diseases Authors: Grebely, J., Mauss, S., Brown, A., Bronowicki, J.-P., Puoti, M., Wyles, D., Natha, M., Zhu, Y., Yang, J., Kreter, B., Brainard, D. M., Yun, C., Carr, V., Dore, G. J. Tags: ARTICLES AND COMMENTARIES Source Type: research